Investors are a little more bullish on the company recently if you consider the change in short interest. Jefferies Group LLC reiterated a "hold" rating and set a $1.25 target price on shares of Alcobra in a research report on Friday, March 31st. The institutional investor owned 472,495 shares of the biotechnology company's stock after buying an additional 458,462 shares during the period. With short interest at 876,447 and short average daily volume at 80,645, the short-interest ratio is 11.0 and the percentage of shorted shares was 0.03% on September 15.
These firms have modified their investment in ADHD.
Recent session action on shares of CorMedix, Inc. Kingdon Capital Management, L.l.c. trimmed its position by shedding 50,479 shares a decrease of 14.4% from 03/31/2017 to 06/30/2017.
Shares of Alcobra (ADHD) opened at 1.12 on Wednesday.
As of the end of the quarter Panagora Asset Management Inc had bought 265,202 shares growing its holdings by 142.1%. The total value of its holdings decreased 16.0%. The value of the investment in (ADHD) increased from $213,000 to $506,000 a change of $293,000 for the reporting period. The value of the investment in Alcobra Ltd. - Ordinary Shares went from $401,000 to $337,000 a change of $64,000 quarter to quarter. WBB Securities raised Alcobra from a hold rating to a buy rating and set a $2.00 target price on the stock in a report on Monday. For the quarter, shares have been noted at -3.95%.
In the market the company is trading unchanged by 0.00% percent from yesterday's close. Checking some other stock price data, we can see that the recent distance from the 50 day high was noted at -8.74% and the separation from the 50 day low is presently 22.43%. The 50 day moving average went up by +10.11% and the 200 day average went up by +5.32%.
In the last earnings report the EPS was $-0.76 and is projected to be $-0.77 for the current year with 27,562,000 shares now outstanding. Equities analysts forecast that Alcobra will post ($0.77) earnings per share for the current fiscal year. The company is primarily developing MDX (metadoxine), an onset/extended release formulation of the chemical pyridoxine pyroglutamate, which is in Phase III clinical trial for adults with attention deficit hyperactivity disorder (ADHD); in Phase II clinical trial for pediatric with ADHD; and which is completed Phase II clinical trial in adolescents and adults with Fragile X Syndrome. Alcobra Ltd. was founded in 2008 and is headquartered in Tel Aviv, Israel.